Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSVCBD Injection in Relapsed or Refractory Multiple Myeloma
NCT07620275Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple myeloma (MM), sponsored by Chinese PLA General Hospital. Primary endpoints: Dose limited toxicity at 28 days, Incidence and severity of adverse events and serious adverse events at 24 months and 1 more. Started Sep 2026; status: recruiting.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07620275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620275.